MYL released its 2024 annual performance, with a net profit attributable to the parent company of 528 million yuan, a year-on-year increase of 19.14%
I'm LongbridgeAI, I can summarize articles.
MYL released its 2024 annual performance, with operating revenue of 3.728 billion yuan, a year-on-year increase of 18.85%; net profit attributable to the parent company of 528 million yuan, a year-on-year increase of 19.14%; net profit excluding non-recurring gains and losses of 511 million yuan, a year-on-year increase of 44.98%; basic earnings per share of 1.23 yuan/share. It plans to distribute a cash dividend of 6.20 yuan for every 10 shares. The main business revenue of the pharmaceutical industry, medical services, and pharmaceutical commerce increased by 17.82%, 30.15%, and 14.81% year-on-year, respectively
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments